Novavax
Novavax
NVAX
NASDAQ
7.38
USD
2.22%
About
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response.
It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates.
Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 4.7M |
| Three Month Average Volume | 203.5M |
| High Low | |
| Fifty-Two Week High | 23.8599 USD |
| Fifty-Two Week Low | 3.5324 USD |
| Fifty-Two Week High Date | 06 Jun 2024 |
| Fifty-Two Week Low Date | 05 Feb 2024 |
| Price and Volume | |
| Current Price | 12.38 USD |
| Beta | 2 |
| Relative Price Change | |
| Four Week Relative Price Change | -0.52% |
| Thirteen Week Relative Price Change | -23.04% |
| Twenty-Six Week Relative Price Change | 108.89% |
| Fifty-Two Week Relative Price Change | 23.50% |
| Year-to-Date Relative Price Change | 117.80% |
| Price Change | |
| One Day Price Change | 8.60% |
| Thirteen Week Price Change | -17.63% |
| Twenty-Six Week Price Change | 129.68% |
| Five Day Price Change | 3.25% |
| Fifty-Two Week Price Change | 54.75% |
| Year-to-Date Price Change | 157.92% |
| Month-to-Date Price Change | -3.36% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | -5.13905 USD |
| Book Value Per Share (Most Recent Quarter) | -2.7 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | -6.05266 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | -3.47163 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -1.80697 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 9.76208 USD |
| Revenue Per Share (Trailing Twelve Months) | 7.41027 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -5.40908 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -2.76357 USD |
| Normalized (Last Fiscal Year) | -5.31684 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -5.40908 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -2.66398 USD |
| Including Extraordinary Items (Last Fiscal Year) | -5.40908 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -2.76357 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 4.07514 USD |
| Cash Per Share (Most Recent Quarter) | 6.56443 USD |
| Cash Flow Per Share (Last Fiscal Year) | -4.87219 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -1.86775 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.1686 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -27 |
| Cash Flow Revenue (Trailing Twelve Months) | -2 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -29.25% |
| Pretax Margin (Last Fiscal Year) | -55.20% |
| Pretax Margin (5 Year) | -75.16% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 65.10% |
| Gross Margin (Trailing Twelve Months) | 63.67% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -57.59% |
| Operating Margin (Trailing Twelve Months) | -29.67% |
| Operating Margin (5 Year) | -74.58% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -55.41% |
| Net Profit Margin (Trailing Twelve Months) | -29.80% |
| Net Profit Margin (5 Year) | -75.94% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -2.11% |
| Revenue Growth (3 Year) | 95.68% |
| Revenue Change (Trailing Twelve Months) | -38.17% |
| Revenue Per Share Growth | 39.40% |
| Revenue Growth (5 Year) | 27.41% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 108.28% |
| Total Debt (5 Year) | -6.42% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 70.86% |
| EPS Change (Trailing Twelve Months) | 61.96% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -816,349,000 |
| Net Debt (Last Fiscal Year) | -339,424,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 2 |
| Price to Sales (Trailing Twelve Months) | 2 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | -100,000 |
| Price to Book (Most Recent Quarter) | -100,000 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | -100,000 |
| Long Term Debt to Equity (Most Recent Quarter) | -100,000 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 1 |
| Quick Ratio (Most Recent Quarter) | 1 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 1 |
| Current Ratio (Most Recent Quarter) | 1 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -767,738,000 |
| Free Cash Flow (Trailing Twelve Months) | -22,472,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -38 |
| Net Interest Coverage (Trailing Twelve Months) | -19 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | -100,000 |
| Total Debt to Equity (Most Recent Quarter) | -100,000 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -26.88% |
| Return on Assets (Trailing Twelve Months) | -16.80% |
| Return on Assets (5 Year) | -46.06% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -99,999.99% |
| Return on Equity (Trailing Twelve Months) | -99,999.99% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -99,999.99% |
| Return on Investment (Trailing Twelve Months) | -78.53% |
| Return on Investment (5 Year) | -269.57% |